A 34-year-old woman with HIV and a CD4 count of 516 cells/mm3 comes to clinic for routine follow-up. She was diagnosed with secondary syphilis 6 months ago, at which time she had a rapid plasma reagin (RPR) titer of 1:256 and received appropriate treatment for syphilis. At this time, the RPR titer has declined to 1:16. She reports one new sex partner since her last visit but denies any genital lesions, rash, fever, lymphadenopathy, ocular symptoms, headache, hearing difficulties, or other symptoms. A complete examination, including a neurologic examination, is unremarkable.
Which one of the following is the most appropriate next course of action?
Figure 1. Comparison of Pretreatment and Post-Treatment Nontreponemal Syphilis Titers
Illustration: David H. Spach, MD
Sign In or Register Progress Not Saved!
Since you are not signed in, your progress won't be saved.
Since you are not signed in, your progress won't be saved.
Question Last Updated
January 29th, 2025
January 29th, 2025
Steps to Acquire CE for this Question Bank Topic:
1
Answer
Answer all questions
2
Score 80%+
Answer correctly
3
Claim CE
Choose CNE or CME
4
Give Feedback
Complete survey
5
Bictegravir-Tenofovir alafenamide-Emtricitabine Biktarvy
Darunavir-Cobicistat-Tenofovir alafenamide-Emtricitabine Symtuza
Dolutegravir-Abacavir-Lamivudine Triumeq
Dolutegravir-Lamivudine Dovato
Dolutegravir-Rilpivirine Juluca
Doravirine-Tenofovir DF-Lamivudine Delstrigo
Efavirenz-Tenofovir DF-Emtricitabine Atripla
Elvitegravir-Cobicistat-Tenofovir alafenamide-Emtricitabine Genvoya
Elvitegravir-Cobicistat-Tenofovir DF-Emtricitabine Stribild
Rilpivirine-Tenofovir alafenamide-Emtricitabine Odefsey
Rilpivirine-Tenofovir DF-Emtricitabine Complera
Fostemsavir Rukobia
Ibalizumab Trogarzo
Maraviroc Selzentry
Dolutegravir Tivicay
Raltegravir Isentress
Tenofovir alafenamide-Emtricitabine Descovy
Tenofovir DF-Emtricitabine Truvada and Multiple Generics
Doravirine Pifeltro
Efavirenz Sustiva
Etravirine Intelence
Rilpivirine Edurant